Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ryan T. Gill
AddedFeb 13, 2024
UpdatedMay 31, 2026
Ryan T. Gill

Ryan T. Gill

CEO, Artisan Bio

CrunchbaseLinkedInThe Org

Ryan T. Gill's Career

Artisan Bio
Artisan Bio

Aurora, CO, US

CEO· C-Suite · Management
Inscripta
Inscripta

Boulder, CO, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ryan T. Gill's Career

Artisan Bio
Artisan Bio
Series A$21M452019Aurora, CO, US
CEO· C-Suite · Management

Leadership at Artisan Bio

Sharon KedarSharon KedarBoard Member
Tanya WarneckeTanya WarneckeFounder
Inscripta
Inscripta
Series A$463.9M1782015Boulder, CO, US
Co-Founder

Leadership at Inscripta

Roger WyseRoger WyseBoard Member
Andrew GarstAndrew GarstCo-Founder
Bryan RobertsBryan RobertsBoard Member
Sri KosarajuSri KosarajuCEO
John StuelpnagelJohn StuelpnagelBoard Member

Similar to Inscripta

SynthegoSynthegoRedwood City, CA, USCrispr Kits, Gene Editingest. 2012SynthegoRedwood City, CA, US · est. 2012

US-based Synthego Corp. provides software solutions for biological research, primarily serving California.

Series E · $460.5M322
Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
Ginkgo BioworksGinkgo BioworksBoston, MA, USOrganism Designest. 2009Ginkgo BioworksBoston, MA, US · est. 2009

Ginkgo Bioworks: Engineering biology, designing custom organisms for diverse markets.

Public · $1.6B1.3k
Tome BiosciencesTome BiosciencesWatertown, MA, USGene Editingest. 2021Tome BiosciencesWatertown, MA, US · est. 2021

Tome Biosciences: Pioneering programmable gene insertion via CRISPR for precise genome editing.

Series A · $213M88

Ryan T. Gill's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Ryan T. Gill

Arturo Loaiza-BonillaArturo Loaiza-BonillaCo-Founder · Massive BioRyan OrizondoRyan OrizondoCo-Founder · Benchtop BioreactorsRachid OunitRachid OunitCo-Founder · BiotiaChristos AlexakosChristos AlexakosCo-Founder · InSyBioAndrew EllingtonAndrew EllingtonCo-Founder · GRO BiosciencesJeffrey L FineJeffrey L FineCo-Founder · SpIntellx